NervGen Pharma: Promising Science, Tight Runway - Trim or Hedge Now
NervGen has a differentiated neuroregenerative approach that could change outcomes in demyelinating and peripheral nerve injury indications. The science is interesting and the stock can rally on positive data or partner news. However, the combination of a narrow cash runway, likely near-term financing, and binary clinical milestones makes the curre…